BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-15 pm EDT 5-day change 1st Jan Change
147.8 USD -2.90% Intraday chart for BeiGene, Ltd. +2.36% -18.07%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating MT
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note MT
Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing MT
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing MT
BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index CI
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma MT
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 CI
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501 CI
Beigene Issues Shares Under Incentive Schemes MT
Transcript : BeiGene, Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy MT
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments MT
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study CI
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa MT
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India MT
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene CI
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT
BeiGene's Q1 Loss Narrows as Revenue Rises MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M MT
Chart BeiGene, Ltd.
More charts
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
147.8 USD
Average target price
263.9 USD
Spread / Average Target
+78.58%
Consensus
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.
  5. BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa